Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D Feasibility): a randomised feasibility trial protocol

  • Andrew J. Farmer
  • , Julie Allen
  • , Kiera Bartlett
  • , Peter Bower
  • , Yuan Chi
  • , David P. French
  • , Bernard Gudgin
  • , Emily Holmes
  • , Rob Horne
  • , Dyfrig Hughes
  • , Cassandra Kenning
  • , Louise Locock
  • , Jennifer McSharry
  • , Lisa Miles
  • , Nikki Newhouse
  • , Rustam Rea
  • , Jenny Riga
  • , Lionel Tarassenko
  • , Carmelo Velardo
  • , Nicola Williams
  • Veronika Williams, Ly-Mee Yu

    Research output: Contribution to journalArticlepeer-review

    176 Downloads (Pure)

    Abstract

    Introduction Type 2 diabetes is common, affecting over 400 million people worldwide. Risk of serious complications can be reduced through use of effective treatments and active self-management. However, people are often concerned about starting new medicines and face difficulties in taking them regularly. Use of brief messages to provide education and support self-management, delivered through mobile phone-based text-messages can be an effective tool for some long-term conditions. We have developed messages aiming to support patients’ self-management of type 2 diabetes in the use of medications and other aspects of self-management, underpinned by theory and evidence. The aim of this trial is to determine the feasibility of a large-scale clinical trial to test the effectiveness and cost-effectiveness of the intervention, compared to usual care.
    Methods and analysis The feasibility trial will be a multi-centre individually randomised, controlled trial in primary care recruiting adults (≥35 years) with type 2 diabetes in England. Consenting participants will be randomised to receive short text-messages three times a week with messages designed to produce change in medication adherence or non-health related messages for six months. The aims are to test recruitment methods, retention to the study, the feasibility of data collection and the mobile-phone and web-based processes of a proposed definitive trial and to refine the text messaging intervention. The primary outcome is the rate of recruitment to randomisation of participants to the trial. Data, including patient reported measures, will be collected online at baseline and the end of the six-month follow-up period. With 200 participants (100 in each group), this trial is powered to estimate 80% follow up within 95% confidence intervals of 73.8% to 85.3%. The analysis will follow a pre-specified plan.
    Original languageEnglish
    Article numbere033504
    JournalBMJ Open
    Volume9
    Issue number12
    Early online date29 Dec 2019
    DOIs
    Publication statusPublished - 29 Dec 2019

    Fingerprint

    Dive into the research topics of 'Supporting people with type 2 diabetes in effective use of their medicine through mobile health technology integrated with clinical care (SuMMiT-D Feasibility): a randomised feasibility trial protocol'. Together they form a unique fingerprint.

    Cite this